{"disease":{"id":"peripheral-t-cell-lymphomas","name":"peripheral t cell lymphomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03922724","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":330,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06176027","title":"Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Navy General Hospital, Beijing","has_results":false},{"nct_id":"NCT07279584","title":"Golidocitinib Combined With GemOx in RR PTCL","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05105412","title":"Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}